Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease; and SC187 for heart failures. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: sana.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/26/2024 | $16.00 | Buy | Rodman & Renshaw |
1/16/2024 | $12.00 | Neutral → Buy | H.C. Wainwright |
9/25/2023 | $9.00 | Mkt Outperform | JMP Securities |
9/5/2023 | $8.00 | Buy | Citigroup |
8/14/2023 | Market Perform | TD Cowen | |
5/2/2023 | Neutral | H.C. Wainwright | |
8/6/2021 | $39.00 → $34.00 | Neutral | Goldman Sachs |
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4/A - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
4 - Sana Biotechnology, Inc. (0001770121) (Issuer)
SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update. Sana will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 11:30 a.m. ET on Wednesday, September 4, 2024.Sana will present at the 2024 Wells Fargo Healthcare Conference at 3:00 p.m. ET on Thursday, September 5, 2024.Sana will present at the HC Wainwright 26th Annual Global Investment Conference at 12:30 p.m. ET on Monday, September 9, 2024. T
Collaboration leverages Quotient's platform to identify somatic mutations in genes that modify the progression of cardiovascular and renal diseases Quotient and Pioneering Medicines, Flagship's in-house drug development unit, will jointly conduct research activities Agreement initiated under strategic partnership between Flagship Pioneering and Pfizer CAMBRIDGE, Mass., Aug. 28, 2024 /PRNewswire/ -- Flagship Pioneering today demonstrated further acceleration in its strategic partnership with Pfizer Inc, announcing two research programs with Flagship-founded Quotient Therapeutics. Under the collaboration, the companies will analyze somatic mutations that occur in diseased patient tissue to inf
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. "We are thrilled to welcome Dhaval to Sana's senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future," said Steve Harr, Sana's President and Chief Executive Officer. "Through decades of experience in research, drug discovery, drug development, and clinical care, Dhaval has successfully led programs in rese
Continue to advance hypoimmune technology in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases; expect to report initial clinical data in 2024 Enrolling patients in two oncology trials – ARDENT for SC291 in B-cell malignancies and VIVID for SC262 in relapsed/refractory B-cell malignancies; expect to report additional clinical data in 2024 Enrolling patients in the investigator-sponsored trial with hypoimmune-modified primary islet cells; expect to report initial clinical data in 2024 Publication in Nature Biotechnology sho
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced that Michelle Seitz, the former Chair and CEO of Russell Investments, has been appointed to serve as an independent director on MSCI's Board of Directors (the "Board"), effective August 5, 2024. Ms. Seitz will serve as a member of the Audit and Risk Committee of the Board. Ms. Seitz's appointment comes after an extensive search initiated last year. "Michelle has deep experience in the investment industry, having spent more than three decades in asset management and private wealth, both as a CEO and as an investor," said Henry A. Fernandez, Chairman and C
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companiesInitial phase to identify and accelerate promising scientific concepts for further research starting in respiratory and immunologyGSK and Flagship to jointly fund up to $150 million upfrontLONDON and CAMBRIDGE, Mass., July 29, 2024 /PRNewswire/ -- GSK plc (NYSE:GSK) and Flagship Pioneering (Flagship), the bioplatform innovation company, today announced they have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines, starting in respiratory and immunology.
Partnership will Leverage Complementary Expertise in Applied Biology and Engineering to Create and Enhance Multiple Digital Biology Platform Companies WILMINGTON, Mass. and CAMBRIDGE, Mass., July 25, 2024 /PRNewswire/ -- Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader, and Flagship Pioneering, the bioplatform innovation company, today announced a strategic alliance to accelerate the development of a fully digitized biological world. This partnership will bridge ADI's expertise in engineering for analog and digital semiconductors with Flagship Pioneering's expertise in applied biology to foster the discovery of biological insights, new and enhanced measurements, diagnostics,
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and promotions. Today's personnel announcement accompanies Flagship's announced expansion of its capital base with a capital pool of $3.6 billion to support the origination and growth of an estimated 25 breakthrough platform companies in human health, sustainability, and AI. Lovisa Afzelius, Ph.D., has been promoted to General Partner. Afzelius joined Flagship in 2020 after leading Pfizer's
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)
10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)
8-K - Sana Biotechnology, Inc. (0001770121) (Filer)
ARS - Sana Biotechnology, Inc. (0001770121) (Filer)
DEFA14A - Sana Biotechnology, Inc. (0001770121) (Filer)
DEF 14A - Sana Biotechnology, Inc. (0001770121) (Filer)
Rodman & Renshaw initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $16.00
H.C. Wainwright upgraded Sana Biotechnology from Neutral to Buy and set a new price target of $12.00
JMP Securities initiated coverage of Sana Biotechnology with a rating of Mkt Outperform and set a new price target of $9.00
Citigroup initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $8.00
TD Cowen initiated coverage of Sana Biotechnology with a rating of Market Perform
H.C. Wainwright initiated coverage of Sana Biotechnology with a rating of Neutral
Goldman Sachs reiterated coverage of Sana Biotechnology with a rating of Neutral and set a new price target of $34.00 from $39.00 previously
The Goldman Sachs Group initiated coverage of Sana Biotechnology with a rating of Neutral and set a new price target of $40.00
Morgan Stanley initiated coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $40.00
JPMorgan Chase & Co. initiated coverage of Sana Biotechnology with a rating of Neutral and set a new price target of $35.00
Shares of The Charles Schwab Corporation (NYSE:SCHW) fell sharply during Tuesday's session following second-quarter results. Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from Benzinga Pro. Charles Schwab shares dipped 7.5% to $69.42 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Yoshitsu Co., Ltd (NASDAQ:TKLF) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results. Silo Pharma, Inc. (NASDAQ:SILO) shares climbed 95.4% to $2.12 after the company obtained an exclusive global l
Healthy transplanted human glial cells replaced diseased glial cells in the brains of human glial chimeric Huntingtin miceAdditional proof-of-concept for the advancement of SC379, Sana's pluripotent stem cell-derived glial progenitor cell product candidate
HC Wainwright & Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:SANA) with a Buy and maintains $12 price target.
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 25.58 percent increase over losses of $(0.43) per share from the same period last year.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PFE CALL SWEEP BULLISH 03/15/24 $27.50 $40.0K 52.1K 6.0K ABBV CALL SWEEP BEARISH 04/19/24 $185.00 $31
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) fell during Monday’s session after the company reportedly saw a decline in February China sales. Tesla sold 60,365 electric vehicles made in China in February, according to preliminary data released by the China Passenger Car Association, as reported by CnEVPost. The breakdown between exports and domestic sales will be available when the detailed report is released in a week. Tesla shares fell 5.4% to $191.79 on Monday. Here are some other big stocks recording losses in today’s session. MMTec, Inc. (NASDAQ:MTC) shares fell 21.8% to $2.00. Avidity Biosciences, Inc
- SEC Filing
Shares of Zscaler, Inc. (NASDAQ:ZS) shares fell sharply during Friday’s session following second-quarter results. Zscaler posted better-than-expected earnings and sales results for its second quarter on Thursday. The company said it expects fiscal year 2024 non-GAAP income from operations between $395 million and $400 million and net income per share between $2.73 and $2.77. Zscaler shares fell 10.1% to $217.43 on Friday. Here are some other stocks moving in today's mid-day session. Gainers BioVie Inc. (NASDAQ:BIVI) shares climbed 96.1% to $2.4319. BioVie's Ne3107 demonstrated potential improvements in motor and non-motor symptoms for Parkinson's disease patients and may be realigni
JMP Securities analyst Reni Benjamin maintains Sana Biotechnology (NASDAQ:SANA) with a Market Outperform and raises the price target from $8 to $15.
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. "We are thrilled to welcome Dhaval to Sana's senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future," said Steve Harr, Sana's President and Chief Executive Officer. "Through decades of experience in research, drug discovery, drug development, and clinical care, Dhaval has successfully led programs in rese
Former White House Top Health Security Official to Lead Flagship's Preemptive Health and Medicine Initiative CAMBRIDGE, Mass., Aug. 6, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced that globally distinguished healthcare expert, entrepreneur, and public policy leader Raj Panjabi, M.D., MPH, will join Flagship as Senior Partner. Dr. Panjabi will lead Flagship's Preemptive Health and Medicine Initiative (PH&M), which is pioneering a new field to protect, maintain, or improve people's health before they get sick. In its fifth year, the initiative is grounded in the premise that health should be accessible for all and pursues interventions that prot
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
O'Shea is a Seasoned Global Executive with more than 20 Years' Experience across the Agriculture, Food and Pharmaceutical Industries CAMBRIDGE, Mass., April 8, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Invaio Sciences, a bioplatform company accelerating the leap to nature-positive agriculture, today announced that Amy O'Shea has joined Flagship Pioneering as CEO-Partner and Invaio as Chief Executive Officer and Board Director. O'Shea is a seasoned global executive with more than 20 years' experience across the agriculture, food, and phar
Banks was Most Recently the President and CEO of Tyson Foods and has been a Board Member of Indigo since July 2022 Company Closes Financing Round at Nearly $270 Million Indigo Also Appoints Nader Bekhouche and Noubar Afeyan to Board of Directors CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Indigo Ag, an innovative leader and trusted partner in sustainable agriculture, today announced that Dean Banks will join Flagship Pioneering as CEO-Partner and CEO of Indigo Ag, effective February 1, 2024. Banks will also continue as an Indigo board member, a role he has held since July 2022. Indigo also announced the appointments of Nader Be
Memorandum of Understanding with UK Government Outlines Areas of Cooperation CAMBRIDGE, Mass. and LONDON, Nov. 27, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today marked the official launch of its UK presence with an event co-hosted in partnership with the UK Government's Office for Life Sciences, bringing together top leaders from industry, government, and academia with a focus on breakthrough innovation. The event marked Flagship's public announcement of its strategic commitment to the UK life sciences ecosystem a week after launching Quotient Therapeutics, its first company located in both the UK and US.
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023. Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse t
ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced the appointment of Klaus Urbahns, Ph.D., as Chief Scientific Officer. Urbahns will lead the Company's platform and drug discovery and development efforts to advance first-in-class therapeutics leveraging the company's ProFoundry™ Platform. Urbahns brings three decades of robust drug discovery and development experience to ProFound, with a successful track record in discovering and advancing first-in-human medicines from the lab to the clinic. He joins ProFound after 13 years at Merck KGaA, where he m
CAMBRIDGE, Mass., Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business Development Officer. In this role, she will be responsible for driving and supporting business development across the Flagship ecosystem, leading the effort to forge strong partnerships between Flagship companies and the biopharma industry. She will also work closely with the Pioneering Medicines unit of Flagship as we continue to invest in and grow our corporate alliance strategy. "Partner
CAMBRIDGE, Mass., Aug. 29, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as Growth Partner. In this role, he will help scale and grow several Flagship-founded companies, working together with leaders at Flagship and its ecosystem of companies on organizational development, long-term strategy, financing, and business development. Khougazian joins Flagship from Sanofi where he spent over two decades most recently leading Sanofi's engagement in global emerging markets inc